Allogeneic Adoptive Immunochemotherapy For Treatment Of Renal Cell Carcinoma
- Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab
in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched
allogeneic stem cell transplantation.
OUTLINE: This is a pilot, multicenter study.
- Conditioning: Patients receive fludarabine IV over 30 minutes on days -6 to -2,
cyclophosphamide IV over 2 hours on days -6 and -5, and alemtuzumab IV on days -4 to
- Allogeneic transplantation: Allogeneic stem cells are infused on day 0. Patients
receive graft-vs-host disease prophylaxis with tacrolimus IV or orally for
approximately 30 days.
Patients are followed weekly for 100 days and then at 6, 12, 18, 24, 36, 48, and 60 months
PROJECTED ACCRUAL: A total of 20 patients (10 with HLA-identical related donors and 10 with
matched unrelated donors) will be accrued for this study.
Primary Purpose: Treatment
Uday Popat, MD
Baylor College of Medicine
United States: Federal Government
|Baylor College of Medicine||Houston, Texas 77030|